MOHFW Will Expedite Serum Institute of India Vaccine Candidate

In the press conference held on July 21, the MOHFW said it will expedite Phase III trials for Serum Institute of India once it applies to the CDSCO for the Oxford-Astrazeneca COVID-19 vaccine, ChAdOx1 nCoV-19. They further spoke about how the CDSCO is now following a process to allow faster approvals of applications.